In castration-sensitive prostate cancer, the incidence of AR-V7 protein expression in metastatic tissue, as measured by IHC, is <0.1% of tumors, but this increases to a 75% incidence in ADT-resistant prostate cancer and >85% in abiraterone and enzalutamide-resistant prostate cancer. This evidence concerns the gene AR and prostate carcinoma.